179 related articles for article (PubMed ID: 24463664)
1. High-risk and low-risk human papillomavirus and the absolute risk of cervical intraepithelial neoplasia or cancer.
Thomsen LT; Frederiksen K; Munk C; Junge J; Castle PE; Iftner T; Kjaer SK
Obstet Gynecol; 2014 Jan; 123(1):57-64. PubMed ID: 24463664
[TBL] [Abstract][Full Text] [Related]
2. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
Kjær SK; Frederiksen K; Munk C; Iftner T
J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
[TBL] [Abstract][Full Text] [Related]
3. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
[TBL] [Abstract][Full Text] [Related]
4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
5. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.
Carozzi F; Gillio-Tos A; Confortini M; Del Mistro A; Sani C; De Marco L; Girlando S; Rosso S; Naldoni C; Dalla Palma P; Zorzi M; Giorgi-Rossi P; Segnan N; Cuzick J; Ronco G;
Lancet Oncol; 2013 Feb; 14(2):168-76. PubMed ID: 23261355
[TBL] [Abstract][Full Text] [Related]
6. Discrepant HPV/cytology cotesting results: Are there differences between cytology-negative versus HPV-negative cervical intraepithelial neoplasia?
Tracht JM; Davis AD; Fasciano DN; Eltoum IA
Cancer Cytopathol; 2017 Oct; 125(10):795-805. PubMed ID: 28817235
[TBL] [Abstract][Full Text] [Related]
7. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
[TBL] [Abstract][Full Text] [Related]
8. [Study on the genotyping of human papillomavirus using a new DNA liquid chip in women of high-risk group of Shandong province].
Liu M; Wang CX; Deng XM; Wang LS; Zhang J; Li W; Zheng GX; Wang JF
Zhonghua Liu Xing Bing Xue Za Zhi; 2007 May; 28(5):487-90. PubMed ID: 17877181
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.
Rodríguez AC; Schiffman M; Herrero R; Hildesheim A; Bratti C; Sherman ME; Solomon D; Guillén D; Alfaro M; Morales J; Hutchinson M; Katki H; Cheung L; Wacholder S; Burk RD
J Natl Cancer Inst; 2010 Mar; 102(5):315-24. PubMed ID: 20157096
[TBL] [Abstract][Full Text] [Related]
10. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance.
Denise Zielinski G; Snijders PJ; Rozendaal L; Voorhorst FJ; Runsink AP; de Schipper FA; Meijer CJ
J Pathol; 2001 Oct; 195(3):300-6. PubMed ID: 11673826
[TBL] [Abstract][Full Text] [Related]
11. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types.
Sand FL; Munk C; Frederiksen K; Junge J; Iftner T; Dehlendorff C; Kjaer SK
Int J Cancer; 2019 Apr; 144(8):1975-1982. PubMed ID: 30246864
[TBL] [Abstract][Full Text] [Related]
12. Impact of the human papillomavirus status on the development of high-grade cervical intraepithelial neoplasia in women negative for intraepithelial lesions or malignancy at the baseline: A 9-year Swedish nested case-control follow-up study.
Fröberg M; Östensson E; Belkić K; Oštrbenk A; Poljak M; Mints M; Arbyn M; Andersson S
Cancer; 2019 Jan; 125(2):239-248. PubMed ID: 30536370
[TBL] [Abstract][Full Text] [Related]
13. Specific human papillomavirus types and other factors on the risk of cervical intraepithelial neoplasia: a case-control study in Korea.
Kim CJ; Lee YS; Kwack HS; Yoon WS; Park TC; Park JS
Int J Gynecol Cancer; 2010 Aug; 20(6):1067-73. PubMed ID: 20683419
[TBL] [Abstract][Full Text] [Related]
14. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: Implications for vaginal self-collection.
Belinson JL; Hu S; Niyazi M; Pretorius RG; Wang H; Wen C; Smith JS; Li J; Taddeo FJ; Burchette RJ; Qiao YL
Int J Cancer; 2010 Sep; 127(5):1151-7. PubMed ID: 20039323
[TBL] [Abstract][Full Text] [Related]
16. Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less.
Pretorius RG; Peterson P; Azizi F; Burchette RJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1260-5. PubMed ID: 17074547
[TBL] [Abstract][Full Text] [Related]
17. Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.
Thomsen LT; Frederiksen K; Munk C; Junge J; Iftner T; Kjaer SK
Int J Cancer; 2015 Jul; 137(1):193-203. PubMed ID: 25471319
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
19. Value of HPV-DNA test in women with cytological diagnosis of atypical glandular cells (AGC).
Zeferino LC; Rabelo-Santos SH; Villa LL; Sarian LO; Costa MC; do Amaral Westin MC; de Ângelo-Andrade LA; Derchain S
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):160-4. PubMed ID: 21680079
[TBL] [Abstract][Full Text] [Related]
20. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology.
Snijders PJ; Hogewoning CJ; Hesselink AT; Berkhof J; Voorhorst FJ; Bleeker MC; Meijer CJ
Int J Cancer; 2006 Sep; 119(5):1102-7. PubMed ID: 16570279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
